For how long should clopidogrel (Plavix) be continued after endovascular aneurysm repair (EVAR)?

Duration of Clopidogrel After EVAR

There is no established guideline-recommended duration for clopidogrel (Plavix) specifically after endovascular aneurysm repair (EVAR), and the available evidence suggests single antiplatelet therapy with aspirin alone may be safer and equally effective in patients without established atherosclerotic cardiovascular disease.

Current Evidence and Recommendations

Guideline Gaps

The most recent 2024 ACC/AHA Lower Extremity PAD Guidelines address antiplatelet therapy after peripheral arterial revascularization but do not provide specific recommendations for EVAR 1. The guidelines recommend:

• After endovascular revascularization for PAD: Dual antiplatelet therapy (DAPT) with a P2Y12 antagonist and low-dose aspirin is reasonable for 1-6 months 1
• After endovascular or surgical revascularization for PAD: Low-dose rivaroxaban (2.5 mg twice daily) combined with low-dose aspirin reduces major adverse cardiovascular events (MACE) and major adverse limb events (MALE) 1

However, these recommendations apply to peripheral arterial disease with atherosclerotic occlusive disease, not aortic aneurysm repair.

Research Evidence on EVAR-Specific Antiplatelet Therapy

The most recent and highest-quality evidence comes from a 2025 target trial emulation study of 8,325 Korean patients undergoing standard EVAR 2. This study found:

• No cardiovascular benefit: DAPT (aspirin plus clopidogrel) showed no reduction in major adverse cardiac and cerebrovascular events compared to single antiplatelet therapy (HR 1.07,95% CI 0.93-1.22) 2
• No procedural benefit: DAPT did not reduce abdominal aortic aneurysm reintervention or surgery rates (HR 1.07,95% CI 0.92-1.24) 2
• Increased bleeding risk: DAPT was associated with significantly higher major or clinically relevant nonmajor bleeding (HR 1.20,95% CI 1.02-1.41) 2

Clinical Implications

For patients WITHOUT established atherosclerotic cardiovascular disease (no prior MI, stroke, or symptomatic PAD):

• Single antiplatelet therapy with aspirin 75-100 mg daily is recommended indefinitely after EVAR 2
• Clopidogrel should not be routinely added for EVAR alone 2

For patients WITH established atherosclerotic cardiovascular disease:

• Follow standard secondary prevention guidelines for their underlying condition 3, 4
• If clopidogrel is indicated for coronary artery disease (post-ACS or post-PCI with stent), continue per cardiac guidelines: at least 12 months for ACS or drug-eluting stents 4, 5
• If clopidogrel is indicated for symptomatic PAD, consider low-dose rivaroxaban (2.5 mg twice daily) plus aspirin as an alternative to reduce both cardiovascular and limb events 1

Important Caveats

Anticoagulation concerns: A 2014 study found that chronic anticoagulation therapy after EVAR was independently associated with increased endoleak rates (OR 1.6) and reintervention/conversion rates (OR 1.8) at mean follow-up of 64 months 6. This suggests caution with prolonged antithrombotic therapy beyond what is medically necessary.

Type II endoleaks: Interestingly, a 2017 study suggested that aspirin therapy may actually reduce aneurysm sac growth in patients with type II endoleaks (HR 0.34,95% CI 0.13-0.87), while multiagent antiplatelet therapy was associated with lack of aneurysm shrinkage 7, 8.

Practical Algorithm

1. At EVAR discharge: Start aspirin 75-100 mg daily indefinitely 2

2. Assess for atherosclerotic cardiovascular disease:

   • If NO prior MI, stroke, or symptomatic PAD: Continue aspirin alone 2
   • If YES (prior ACS/MI): Add clopidogrel 75 mg daily for at least 12 months per cardiac guidelines 4, 5
   • If YES (symptomatic PAD): Consider rivaroxaban 2.5 mg twice daily plus aspirin instead of DAPT 1

3. Avoid routine DAPT for EVAR alone: The bleeding risk outweighs any unproven benefit 2